Regeneron Pharmaceuticals

From Wikipedia, the free encyclopedia
  (Redirected from Regeneron)
Jump to navigation Jump to search
Regeneron Pharmaceuticals, Inc.
Traded as
ISINUS75886F1075 Edit this on Wikidata
IndustryPharmaceuticals; Biotech
Founded1988; 32 years ago (1988)
HeadquartersEastview, New York, US (Headquarters)
Area served
Key people
RevenueIncrease $7.86 billion (2019)[1]
Increase $1.4 billion[2]
Total assetsIncrease $5.6 billion[2]
Number of employees
8,100 [3] (2019)

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York, according to the company's website. The company was founded in 1988.[4] Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

Company history[edit]

Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.

On March 26, 2012, Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. The new drug targets the PCSK9 gene.[5][citation needed]

In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[6] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[7] REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best stock of the 2010s, with a total return of 1,457%.[8]

Regeneron Pharmaceuticals was home to the two highest-paid pharmaceutical executives as of 2020.[9]

During the COVID-19 pandemic, in early 2020, Regeneron made a deal with the US-government Biomedical Advanced Research and Development Authority that the government would fund 80% of the costs for Regeneron to develop and manufacture Coronavirus disease 2019 treatments, and Regeneron would retain the right to set prices and control production. This deal was criticized in the New York Times. Such deals are not unusual for routine drug development in the American pharmaceutical market.[9]

In May 2020 Regeneron announced it would repurchase around $5 billion of its shares, held directly by Sanofi. Prior to the transaction Sanofi held 23.2 million Regeneron shares.[10]

Marketed products[edit]

ARCALYST (rilonacept) for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.

EYLEA (aflibercept injection) Approved by the U.S. Food and Drug Administration (FDA) in November 2011[4][11] to treat a common cause of blindness in the elderly. EYLEA is reported to cost $11,000 per year for each eye treated.[12]

ZALTRAP (aflibercept injection) for metastatic colorectal cancer: Approved by the FDA in August 2012.[13]

PRALUENT (alirocumab) indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by FDA on 24 July 2015 [14] It is reported to cost $4,500 to $8,000 per year.[15]

DUPIXENT (dupilumab injection) is for the treatment of adolescent and adult patients' atopic dermatitis. Approved by FDA on 28 March 2017.[16] It is reported to cost $37,000 per year.[12]

KEVZARA (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment of adult patients with rheumatoid arthritis. Approved by FDA on 22 May 2017.[17] Trials commenced on March 16 2020 to evaluate the effectiveness of Kevzara in the treatment of COVID-19.[18][19]

LIBTAYO (cemiplimab injection) is a monoclonal antibody targeting the PD-1 pathway as a checkpoint inhibitor, for the treatment of patients with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Approved by FDA on 28 September 2018.[20]

REGN-EB3 is a drug made of three antibodies, developed to treat Ebola. Among patients treated with it, 71% recovered; the mortality rate improved if the drug was administered soon after infection, at a 94% survival rate, in a timely diagnosis- critical for those infected with dangerous diseases like Ebola that can cause sepsis and, eventually, multiple organ dysfunction syndrome, more quickly than other diseases. This makes Ebola potentially a treatable disease.[21]

Technology platforms[edit]

Trap Fusion Proteins: Regeneron's novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.

Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.[22]:255–258

Financial performance[edit]

Financial Year Revenue Ref
2012 $1.4 billion [23]
2013 $2.1 billion [24]
2014 $2.8 billion [25]
2015 $4.1 billion [26]
2016 $4.8 billion [27]
2017 $5.8 billion [28]
2018 $6.7 billion [29]
2019 $7.8 billion [30]

Key people[edit]

The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos. They are reported to hold $1.3 billion and $900 million in company stock, respectively. Both are from Queens, New York.[12]

Schleifer was formerly a professor of medicine at Weill Cornell Medical School. Yancopoulos was an assistant professor at Columbia University. Yancopoulos was involved in each drug's development.[12]

See also[edit]


  1. ^
  2. ^ a b [1][dead link]
  3. ^
  4. ^ a b Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. United States. Archived from the original on March 16, 2014. Retrieved March 22, access
  5. ^ Husten, Larry. "Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race". Forbes. Retrieved 2018-02-22.
  6. ^ "Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration - GEN News Highlights - GEN". 2015-07-28.
  7. ^ "UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology - FierceBiotech".
  8. ^ Hough, Jack. "10 Stocks That Had Better Decades Than Amazon and Google". Retrieved 2019-12-19.
  9. ^ a b Mazzucato, Mariana; Momenghalibaf, Azzi (18 March 2020). "Drug Companies Will Make a Killing From Coronavirus". The New York Times.
  10. ^
  11. ^ "Regulators Approve a Drug for an Eye Condition". The New York Times. Associated Press. November 18, 2011.(registration required)
  12. ^ a b c d "Regeneron's Billionaire Founder Battles The Drug Pricing System". Forbes. 26 July 2018. Retrieved 26 July 2018.
  13. ^ "FDA approves Zaltrap for metastatic colorectal cancer" (Press release). U.S. Food and Drug Administration. August 3, 2012. Archived from the original on June 25, 2013.
  14. ^ "Archived copy". Archived from the original on 2015-07-27. Retrieved 2015-07-29.CS1 maint: archived copy as title (link)
  15. ^ Tirrell, Meg (2018-05-01). "A $14,000 cholesterol drug gets a price cut as Regeneron, Sanofi strike deal with Express Scripts". CNBC. Retrieved 2018-08-22.
  16. ^ Inc., Regeneron Pharmaceuticals. "Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis".
  17. ^ "Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (NASDAQ:REGN)".
  18. ^ "Regeneron's COVID-19 Response Efforts".
  19. ^ "Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19".
  20. ^ "FDA approves first treatment for advanced form of the second most common skin cancer (NASDAQ:REGN)". 2019-09-11.
  21. ^ "'Ebola is Now a Disease We Can Treat.' How a Cure Emerged from a War Zone".
  22. ^ Susana Magadán Mompó and África González-Fernández. Human Monoclonal Antibodies from Transgenic Mice. Chapter 13 in Human Monoclonal Antibodies: Methods and Protocols Ed. Michael Steinitz. Springer Science+Business Media, 2014. ISBN 978-1-62703-585-9
  23. ^ "REGENERON PHARMACEUTICALS INC 2013 Annual Report Form (10-K)" (XBRL). United States Securities and Exchange Commission. February 13, 2014.
  24. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.
  25. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.
  26. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.
  27. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.
  28. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.
  29. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.
  30. ^ "Regeneron Pharmaceuticals Revenue 2006-2020 | REGN". Retrieved 2020-06-12.

External links[edit]